**Supplementary Table1. Price, expenditures, and growth rate of hepatitis B antiviral drugs from April 2018 to March 2021 using USD**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hepatitis B antiviral drugs | Expenditures (million USD) | | | | | Price (USD) | | | | |
| April 2018–March 2019 | April 2019–March 2020 | April 2020–March 2021 | Average GR (%) | Cumulative GR (%) | April 2018–March 2019 | April 2019–March 2020 | April 2020–March 2021 | Average GR (%) | Cumulative GR (%) |
| Total | 1021.95 | 751.01 | 310.29 | -42.6 | -69.64 | 1.71 | 0.77 | 0.32 | -56.69 | -81.28 |
| ETV | 796.31 | 554.54 | 202.82 | -46.89 | -74.53 | 1.86 | 0.73 | 0.27 | -62.18 | -85.71 |
| TDF | 65.42 | 90.03 | 51.04 | -2.84 | -21.97 | 2.22 | 0.82 | 0.46 | -53.16 | -79.03 |
| ADV | 69.74 | 45.00 | 12.32 | -54.05 | -82.33 | 0.85 | 0.82 | 0.22 | -38.41 | -73.76 |
| LAM | 55.15 | 37.59 | 26.19 | -31.08 | -52.51 | 1.21 | 1.13 | 0.79 | -18.73 | -35.30 |
| Ltd | 35.34 | 23.86 | 17.91 | -28.72 | -49.33 | 2.65 | 2.64 | 1.98 | -12.73 | -25.34 |
| Drugs in the bid-winning list |  |  |  |  |  |  |  |  |  |  |
| Total | 15.24 | 22.20 | 22.09 | 22.57 | 44.92 | 0.76 | 0.07 | 0.07 | -45.47 | -90.50 |
| ETV | 12.33 | 12.54 | 14.35 | 8.07 | 16.39 | 0.71 | 0.05 | 0.06 | -39.29 | -92.02 |
| TDF | 2.91 | 9.66 | 7.74 | 105.93 | 165.78 | 1.08 | 0.18 | 0.15 | -51.46 | -86.41 |
| Drugs in the non-bid-winning list |  |  |  |  |  |  |  |  |  |  |
| Total | 1006.71 | 728.81 | 288.20 | -44.03 | -71.37 | 1.74 | 1.10 | 0.43 | -48.71 | -75.07 |
| ETV | 783.98 | 542.00 | 188.47 | -48.05 | -75.96 | 1.91 | 1.06 | 0.37 | -54.73 | -80.61 |
| TDF | 62.50 | 80.37 | 43.31 | -8.77 | -30.71 | 2.33 | 1.41 | 0.76 | -42.94 | -67.54 |
| ADV | 69.74 | 45.00 | 12.32 | -54.05 | -82.33 | 0.85 | 0.82 | 0.22 | -38.41 | -73.76 |
| LAM | 55.15 | 37.59 | 26.19 | -31.08 | -52.51 | 1.21 | 1.13 | 0.79 | -18.73 | -35.30 |
| Ltd | 35.34 | 23.86 | 17.91 | -28.72 | -49.33 | 2.65 | 2.64 | 1.98 | -12.73 | -25.34 |

Adefovir, ADV; ETV, entecavir; GR, growth rate; LAM, lamivudine; Ltd, telbivudine; RMB, renminbi; TDF, tenofovir disoproxil fumarate; USD, United States dollar.